-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical Network, June 22 News On June 21, the official website of the State Food and Drug Administration showed that Qilu Pharmaceutical's Levosimendan injection and rasagiline mesylate tablets were approved for production and deemed to have been reviewed
.
According to data from Menet.
com, Qilu’s rasagiline mesylate tablets are the first imitation in China, and the sales of the original products in the domestic market will rise by more than 300% in 2020; Levosimendan injection will be in the end of China’s public medical institutions in 2020 With sales of nearly 600 million yuan, Qilu's products are the first to have been reviewed
.
.
According to data from Menet.
com, Qilu’s rasagiline mesylate tablets are the first imitation in China, and the sales of the original products in the domestic market will rise by more than 300% in 2020; Levosimendan injection will be in the end of China’s public medical institutions in 2020 With sales of nearly 600 million yuan, Qilu's products are the first to have been reviewed
.
Rasagiline is an irreversible selective inhibitor of MAO-B, which can increase the level of extracellular dopamine in the striatum.
It is clinically suitable for the monotherapy of patients with primary Parkinson's disease (without levodopa), and as a levodopa Pakistan's adjuvant medication is used for Parkinson's patients with end-of-dose fluctuations
.
It is clinically suitable for the monotherapy of patients with primary Parkinson's disease (without levodopa), and as a levodopa Pakistan's adjuvant medication is used for Parkinson's patients with end-of-dose fluctuations
.
The original research product was approved to enter the domestic market in June 2017, and currently no generic drugs have been approved for listing
.
According to data from Mi Nei.
com, the total sales of this product in China's urban public hospitals , county-level public hospitals, urban community centers, township health centers (referred to as Chinese public medical institutions) and Chinese urban physical pharmacies in 2020 are nearly 50 million yuan, a year-on-year increase 328.
72%
.
.
According to data from Mi Nei.
com, the total sales of this product in China's urban public hospitals , county-level public hospitals, urban community centers, township health centers (referred to as Chinese public medical institutions) and Chinese urban physical pharmacies in 2020 are nearly 50 million yuan, a year-on-year increase 328.
72%
.
Sales of rasagiline mesylate tablets in terminal pharmacies in Chinese cities (unit: ten thousand yuan)
Source: Mi Nei.
com, China's urban physical pharmacy terminal competition pattern
com, China's urban physical pharmacy terminal competition pattern
There are currently three companies to submit a new registration classification rasagiline mesylate tablets listing application, the first newspaper Qilu Pharmaceutical products industry, the first to win the first copy
.
.
Production status of new classification of rasagiline mesylate tablets
Source: One-click search on Mi Nei.
com
com
Levosimendan injection is a calcium sensitizer.
It is suitable for short-term acute decompensated heart failure in which traditional treatments (diuretics, angiotensin-converting enzyme inhibitors and digitalis) have poor efficacy and require increased myocardial contractility.
Treatment
.
It is suitable for short-term acute decompensated heart failure in which traditional treatments (diuretics, angiotensin-converting enzyme inhibitors and digitalis) have poor efficacy and require increased myocardial contractility.
Treatment
.
At present, there are two domestic enterprises and one multinational company that have production approval for Levosimendan injection.
According to data from Meinenet, the sales of this product in China's public medical institutions in 2020 will be close to 600 million yuan, a year-on-year increase of 13.
58%
.
According to data from Meinenet, the sales of this product in China's public medical institutions in 2020 will be close to 600 million yuan, a year-on-year increase of 13.
58%
.
Two companies, Qilu Pharmaceutical (Hainan) and Yangzijiang, submitted applications for the listing of Levosimendan injection under the new registration classification.
Among them, Qilu Pharmaceutical (Hainan)'s products were approved for production and deemed to have been reviewed, making it the first in China
.
Among them, Qilu Pharmaceutical (Hainan)'s products were approved for production and deemed to have been reviewed, making it the first in China
.
Source: Mynet database, official website of the State Drug Administration
Medical Network, June 22 News On June 21, the official website of the State Food and Drug Administration showed that Qilu Pharmaceutical's Levosimendan injection and rasagiline mesylate tablets were approved for production and deemed to have been reviewed
.
According to data from Menet.
com, Qilu’s rasagiline mesylate tablets are the first imitation in China, and the sales of the original products in the domestic market will rise by more than 300% in 2020; Levosimendan injection will be in the end of China’s public medical institutions in 2020 With sales of nearly 600 million yuan, Qilu's products are the first to have been reviewed
.
.
According to data from Menet.
com, Qilu’s rasagiline mesylate tablets are the first imitation in China, and the sales of the original products in the domestic market will rise by more than 300% in 2020; Levosimendan injection will be in the end of China’s public medical institutions in 2020 With sales of nearly 600 million yuan, Qilu's products are the first to have been reviewed
.
Rasagiline is an irreversible selective inhibitor of MAO-B, which can increase the level of extracellular dopamine in the striatum.
It is clinically suitable for the monotherapy of patients with primary Parkinson's disease (without levodopa), and as a levodopa Pakistan's adjuvant medication is used for Parkinson's patients with end-of-dose fluctuations
.
It is clinically suitable for the monotherapy of patients with primary Parkinson's disease (without levodopa), and as a levodopa Pakistan's adjuvant medication is used for Parkinson's patients with end-of-dose fluctuations
.
The original research product was approved to enter the domestic market in June 2017, and currently no generic drugs have been approved for listing
.
According to data from Mi Nei.
com, the total sales of this product in China's urban public hospitals , county-level public hospitals, urban community centers, township health centers (referred to as Chinese public medical institutions) and Chinese urban physical pharmacies in 2020 are nearly 50 million yuan, a year-on-year increase 328.
72%
.
.
According to data from Mi Nei.
com, the total sales of this product in China's urban public hospitals , county-level public hospitals, urban community centers, township health centers (referred to as Chinese public medical institutions) and Chinese urban physical pharmacies in 2020 are nearly 50 million yuan, a year-on-year increase 328.
72%
.
Sales of rasagiline mesylate tablets in terminal pharmacies in Chinese cities (unit: ten thousand yuan)
Source: Mi Nei.
com, China's urban physical pharmacy terminal competition pattern
com, China's urban physical pharmacy terminal competition pattern
There are currently three companies to submit a new registration classification rasagiline mesylate tablets listing application, the first newspaper Qilu Pharmaceutical products industry, the first to win the first copy
.
.
Production status of new classification of rasagiline mesylate tablets
Source: One-click search on Mi Nei.
com
com
Levosimendan injection is a calcium sensitizer.
It is suitable for short-term acute decompensated heart failure in which traditional treatments (diuretics, angiotensin-converting enzyme inhibitors and digitalis) have poor efficacy and require increased myocardial contractility.
Treatment
.
It is suitable for short-term acute decompensated heart failure in which traditional treatments (diuretics, angiotensin-converting enzyme inhibitors and digitalis) have poor efficacy and require increased myocardial contractility.
Treatment
.
At present, there are two domestic enterprises and one multinational company that have production approval for Levosimendan injection.
According to data from Meinenet, the sales of this product in China's public medical institutions in 2020 will be close to 600 million yuan, a year-on-year increase of 13.
58%
.
According to data from Meinenet, the sales of this product in China's public medical institutions in 2020 will be close to 600 million yuan, a year-on-year increase of 13.
58%
.
Two companies, Qilu Pharmaceutical (Hainan) and Yangzijiang, submitted applications for the listing of Levosimendan injection under the new registration classification.
Among them, Qilu Pharmaceutical (Hainan)'s products were approved for production and deemed to have been reviewed, making it the first in China
.
Among them, Qilu Pharmaceutical (Hainan)'s products were approved for production and deemed to have been reviewed, making it the first in China
.
Source: Mynet database, official website of the State Drug Administration
Medical Network, June 22 News On June 21, the official website of the State Food and Drug Administration showed that Qilu Pharmaceutical's Levosimendan injection and rasagiline mesylate tablets were approved for production and deemed to have been reviewed
.
According to data from Menet.
com, Qilu’s rasagiline mesylate tablets are the first imitation in China, and the sales of the original products in the domestic market will rise by more than 300% in 2020; Levosimendan injection will be in the end of China’s public medical institutions in 2020 With sales of nearly 600 million yuan, Qilu's products are the first to have been reviewed
.
.
According to data from Menet.
com, Qilu’s rasagiline mesylate tablets are the first imitation in China, and the sales of the original products in the domestic market will rise by more than 300% in 2020; Levosimendan injection will be in the end of China’s public medical institutions in 2020 With sales of nearly 600 million yuan, Qilu's products are the first to have been reviewed
.
Rasagiline is an irreversible selective inhibitor of MAO-B, which can increase the level of extracellular dopamine in the striatum.
It is clinically suitable for the monotherapy of patients with primary Parkinson's disease (without levodopa), and as a levodopa Pakistan's adjuvant medication is used for Parkinson's patients with end-of-dose fluctuations
.
It is clinically suitable for the monotherapy of patients with primary Parkinson's disease (without levodopa), and as a levodopa Pakistan's adjuvant medication is used for Parkinson's patients with end-of-dose fluctuations
.
The original research product was approved to enter the domestic market in June 2017, and currently no generic drugs have been approved for listing
.
According to data from Mi Nei.
com, the total sales of this product in China's urban public hospitals , county-level public hospitals, urban community centers, township health centers (referred to as Chinese public medical institutions) and Chinese urban physical pharmacies in 2020 are nearly 50 million yuan, a year-on-year increase 328.
72%
.
Hospital hospital hospital pharmacy pharmacy pharmacy.
According to data from Mi Nei.
com, the total sales of this product in China's urban public hospitals , county-level public hospitals, urban community centers, township health centers (referred to as Chinese public medical institutions) and Chinese urban physical pharmacies in 2020 are nearly 50 million yuan, a year-on-year increase 328.
72%
.
Sales of rasagiline mesylate tablets in terminal pharmacies in Chinese cities (unit: ten thousand yuan)
Source: Mi Nei.
com, China's urban physical pharmacy terminal competition pattern
com, China's urban physical pharmacy terminal competition pattern
There are currently three companies to submit a new registration classification rasagiline mesylate tablets listing application, the first newspaper Qilu Pharmaceutical products industry, the first to win the first copy
.
Enterprise business enterprise.
Production status of new classification of rasagiline mesylate tablets
Source: One-click search on Mi Nei.
com
com
Levosimendan injection is a calcium sensitizer.
It is suitable for short-term acute decompensated heart failure in which traditional treatments (diuretics, angiotensin-converting enzyme inhibitors and digitalis) have poor efficacy and require increased myocardial contractility.
Treatment
.
It is suitable for short-term acute decompensated heart failure in which traditional treatments (diuretics, angiotensin-converting enzyme inhibitors and digitalis) have poor efficacy and require increased myocardial contractility.
Treatment
.
At present, there are two domestic enterprises and one multinational company that have production approval for Levosimendan injection.
According to data from Meinenet, the sales of this product in China's public medical institutions in 2020 will be close to 600 million yuan, a year-on-year increase of 13.
58%
.
According to data from Meinenet, the sales of this product in China's public medical institutions in 2020 will be close to 600 million yuan, a year-on-year increase of 13.
58%
.
Two companies, Qilu Pharmaceutical (Hainan) and Yangzijiang, submitted applications for the listing of Levosimendan injection under the new registration classification.
Among them, Qilu Pharmaceutical (Hainan)'s products were approved for production and deemed to have been reviewed, making it the first in China
.
Among them, Qilu Pharmaceutical (Hainan)'s products were approved for production and deemed to have been reviewed, making it the first in China
.
Source: Mynet database, official website of the State Drug Administration
